Journal Browser Advanced Search Help
Journal Browser Advanced search HELP
Ann Lab Med. 2018 Mar;38(2):160-164. English. Brief Communication. https://doi.org/10.3343/alm.2018.38.2.160
Yang N , Mun YC , Seong CM , Huh HJ , Huh J .
Department of Laboratory Medicine, College of Medicine, Ewha Womans University, Seoul, Korea. JungWonH@ewha.ac.kr
Department of Internal Medicine, College of Medicine, Ewha Womans University, Seoul, Korea.
Department of Laboratory Medicine, Dongguk University, Ilsan Medical Center, Goyang, Korea. hjhuh@duih.org
Abstract

In multiple myeloma (MM), hyperdiploidy (HD) is known to impart longer overall survival. However, it is unclear whether coexistent HD ameliorates the adverse effects of known high-risk cytogenetics in MM patients. To address this issue, we investigated the clinicopathological characteristics of HD with high-risk cytogenetics in MM. Ninety-seven patients with MM were included in the study. For metaphase cytogenetics (MC), unstimulated cells from bone marrow aspirates were cultured for either 24 or 48 hours. To detect HD by interphase fluorescence in situ hybridization (iFISH), we assessed trisomies of chromosomes 5, 7, 9, 11, 15, and 17. Of the 97 MM patients, 40 showed HD. The frequency of co-occurrence of HD and high-risk cytogenetics was 14% (14/97). When the clinicopathological characteristics were compared between the two groups of HD with high-risk cytogenetics vs. non-HD (NHD) with high-risk cytogenetics, the level of beta 2 microglobulin and stage distribution significantly differed (P=0.020, P=0.032, respectively). This study shows that some of the clinicopathological characteristics of MM patients with high-risk cytogenetics differ according to HD or NHD status.

Copyright © 2019. Korean Association of Medical Journal Editors.